[Mouse models of hematological diseases using genome editing technology].

The impact of gene-editing technology has rapidly expanded into developmental engineering. Using this technology, gene targeting in mice can be performed within 2-3 months, which is a much shorter timespan than that required while using embryonic stem cell-based conventional methods, which require nearly two years. In addition, genome-editing technology omits several skillful laborious steps. This review describes the prominent merits of gene targeting using this recently established and still ongoing technology in the field of hematology. In addition, the experience of the authors is reviewed to identify and characterize genes involved in the loss of the long arm of chromosome 7 in myeloid malignancies and highlight the significance of establishing the mouse model of human diseases.